Gedeon Richter Provides Clues On Key Biosimilar Trial Dates

Denosumab And Tocilizumab In Richter’s Pipeline

 
• By Dean Rudge
  
Open doors
Richter will continue to grow R&D spending in 2021, given that CNS and in biosimilars projects are entering into the clinical phase • Source: Shutterstock

More from Biosimilars

More from Products